Abstract
Background: Optimal management of anti-CD20-treated patients with multiple sclerosis (pwMS) is an important clinical task during the current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic.
Objectives: To characterize humoral and cellular immune responses to SARS-CoV-2 vaccinations/infections in a longitudinal cohort of anti-CD20 treated ( n = 175) and anti-CD20 therapy-naïve ( n = 41) pwMS.
Methods: Anti-SARS-CoV-2 spike protein immunoglobulin G (IgG) and IgA, virus neutralizing capacity, IgG avidity and SARS-CoV-2-specific T cells were determined.
Results: Following two SARS-CoV-2 vaccinations, not only SARS-CoV-2 spike protein IgG and IgA, but also neutralizing capacity and avidity of SARS-CoV-2 IgG were lower in anti-CD20-treated ( n = 51) than in anti-CD20 therapy-naïve pwMS ( n = 14) and in healthy controls (HC, n = 19). However, in all anti-CD20-treated pwMS vaccinated twice ( n = 26) or infected with SARS-CoV-2 ( n = 2), in whom SARS-CoV-2-specific T cells were measured, SARS-CoV-2-specific T cells were detectable, at levels similar to those of twice-vaccinated anti-CD20 therapy-naïve pwMS ( n = 7) and HC ( n = 19). SARS-CoV-2-S1 IgG levels ( r = 0.42, p = 0.002), antibody avidity ( r = 0.7, p < 0.001), and neutralizing capacity ( r = 0.44, p = 0.03) increased with time between anti-CD20 infusion and second vaccination. Based on detection of SARS-CoV-2 antibodies, SARS-CoV-2 infections occurred in 4 out of 175 (2.3%) anti-CD20-treated pwMS, all of whom recovered fully.
Conclusions: These findings should inform treatment decisions and SARS-CoV-2 vaccination management in pwMS.
Keywords: Multiple sclerosis; SARS-CoV-2; T cells; anti-CD20 therapy; antibodies; vaccination.
【저자키워드】 antibodies, SARS-CoV-2, vaccination, multiple sclerosis, T cells, anti-CD20 therapy, 【초록키워드】 Treatment, IgG, vaccination, pandemic, multiple sclerosis, Cellular immune response, T cells, SARS-COV-2 infection, virus, anti-SARS-CoV-2, anti-CD20 therapy, Spike protein, Cohort, Immunoglobulin G, SARS-CoV-2 antibodies, Immunoglobulin, IgA, immune responses, management, SARS-CoV-2 spike protein, Patient, neutralizing capacity, avidity, respiratory, SARS-CoV-2 infections, SARS-CoV-2 IgG, SARS-CoV-2 vaccination, Antibody avidity, SARS-CoV-2-specific T cells, anti-CD20, Humoral and cellular immune responses, CD20, Coronavirus-2, Vaccinations, humoral, acute respiratory syndrome, acute respiratory syndrome coronavirus, second vaccination, healthy control, acute respiratory syndrome coronavirus-2, IgG levels, healthy controls, Multiple, anti-SARS-CoV-2 spike protein, occurred, detectable, treated, were measured, IgG level, infected with SARS-CoV-2, SARS-CoV-2-specific T cell, 【제목키워드】 T cell response, treated,